AB SCIEX and the University of Melbourne today announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals.
AB SCIEX and the University of Melbourne today announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals.
This project is focused on developing a standardized testing methodology based on an approach pioneered by scientists at the University of Melbourne on the AB SCIEX QTRAP 5500 system. The approach would allow scientists to follow the fate of the breakdown of protein-based drugs in vivo. This could help drug discovery scientists better determine the effectiveness and safety of peptide and protein therapeutic agents that are advanced through regulatory processes and ultimately sold on the consumer market.
“Targeting the unknown breakdown products of a biologic without knowing what they are is revolutionary in the biopharmaceutical industry. The technology we are developing with AB SCIEX will give scientists the unique ability to produce metabolism profiles for peptide and protein drugs that the industry simply cannot do right now. This is essential for advancing an increasing number of biopharma drugs to market,” said Anthony Purcell, associate professor, senior research fellow and a principal investigator at the department of biochemistry and molecular biology, the Bio21 Molecular Science and Biotechnology Institute at the University of Melbourne.
For more information visit www.absciex.com
Inside the Laboratory: The Gionfriddo Group at the University at Buffalo
March 28th 2024In this edition of “Inside the Laboratory,” Emanuela Gionfriddo, PhD, an associate professor of chemistry at the University at Buffalo, discusses her group’s current research endeavors, including using solid-phase microextraction (SPME) coupled to liquid chromatography (LC) and gas chromatography (GC) to further understand the chemical relationship between environmental exposure and disease and elucidate micropollutants fate in the environment and biological systems.
Transferring Methods to Compact and Portable HPLC
February 14th 2024The current trend in laboratory equipment design is the miniaturization of laboratory instruments. Smaller-scale HPLC instruments offer benefits that cannot be matched by analytical-scale equipment, especially in the areas of portability, reduced fluid volumes, and reduced operating costs. Yet, the miniaturization of laboratory equipment has brought with it a unique set of challenges, including transferring methods to compact LC. Capillary LC expands the use of LC to applications not currently done using conventional LC in a wide array of application areas, including pharmaceutical, food and beverage, petrochemical, environmental, and oil and gas. Greg Ward, Axcend’s CEO wrote, “Customers want an HPLC system with a small footprint, low flow rates and green chemistry.” Join his podcast where he shares method transfer in these application areas.